Incidence and risk factors for musculoskeletal adverse effects associated with daptomycin in patients receiving outpatient parenteral antimicrobial therapy
Abstract Background: Daptomycin is preferred in outpatient parenteral antimicrobial therapy (OPAT) due to daily dosing. Elevations in creatine phosphokinase (CPK) of 3%–10% and musculoskeletal adverse events have been described with daptomycin, but data regarding risk factors and frequency of moni...
Saved in:
Main Authors: | Meaghen B. Wiley, Kiya K. Bennett, Emily A. Siegrist, Stephen B. Neely, Joseph Sassine, Bryan P. White |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2025-01-01
|
Series: | Antimicrobial Stewardship & Healthcare Epidemiology |
Online Access: | https://www.cambridge.org/core/product/identifier/S2732494X25100879/type/journal_article |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Commentary: Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)
by: Matthew Warren Brunke, et al.
Published: (2025-07-01) -
Evaluation of the outpatient parenteral antimicrobial therapy (OPAT) service in Malaysian public hospitals: a mixed-methods study protocol
by: Nor Arisah Misnan, et al.
Published: (2025-06-01) -
Genetic Correlates of Synergy Mechanisms of Daptomycin Plus Fosfomycin in Daptomycin-Susceptible and -Resistant Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA)
by: Warren E. Rose, et al.
Published: (2025-06-01) -
Use of Daptomycin to Manage Severe MRSA Infections in Humans
by: Marco Fiore, et al.
Published: (2025-06-01) -
Influence of renal function and daptomycin dose on clinical effectiveness and adverse events in Japanese pediatric patients: A multicenter retrospective observational study.
by: Chihiro Shiraishi, et al.
Published: (2025-01-01)